- Report
- September 2023
- 100 Pages
Global
From €5717EUR$5,950USD£4,908GBP
- Report
- March 2019
- 124 Pages
Global
From €1321EUR$1,375USD£1,134GBP
€2642EUR$2,750USD£2,268GBP
- Report
- June 2018
- 99 Pages
Global
From €5717EUR$5,950USD£4,908GBP
- Report
- March 2023
- 115 Pages
Global
From €4708EUR$4,900USD£4,042GBP
- Report
- June 2022
- 117 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3123EUR$3,250USD£2,681GBP
- Report
- February 2022
- 308 Pages
Global
From €9128EUR$9,500USD£7,836GBP
- Report
- August 2022
- 113 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Newsletter
- May 2024
- 14 Pages
United Kingdom
- Newsletter
- May 2024
- 14 Pages
United States
- Report
- September 2018
- 630 Pages
Global
From €21139EUR$22,000USD£18,146GBP
- Report
- October 2021
- 131 Pages
Global
From €10564EUR$10,995USD£9,069GBP
- Report
- February 2022
- 40 Pages
India
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2022
- 40 Pages
Saudi Arabia
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2022
- 100 Pages
Global
From €4607EUR$4,795USD£3,955GBP
- Report
- January 2019
- 35 Pages
Global
From €961EUR$1,000USD£825GBP
- Report
- May 2021
- 88 Pages
Global
€21139EUR$22,000USD£18,146GBP
- Report
- August 2018
- 17 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- February 2022
- 80 Pages
Africa
From €3646EUR$3,795USD£3,130GBP
- Report
- February 2022
- 40 Pages
Brazil
From €2493EUR$2,595USD£2,140GBP
Erbitux is a monoclonal antibody drug used to treat certain types of cancer, including lung cancer. It works by blocking the action of a protein called epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. This helps to slow down or stop the growth of the cancer cells. Erbitux is usually used in combination with other chemotherapy drugs to treat advanced non-small cell lung cancer (NSCLC). It is also used to treat head and neck cancer, colorectal cancer, and other types of cancer.
Erbitux is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and other types of cancer. It is available in both intravenous and oral formulations. The drug is marketed by Merck & Co. in the United States and by Bristol-Myers Squibb in Europe. Other companies involved in the Erbitux market include Amgen, AstraZeneca, and Eli Lilly. Show Less Read more